Harvoni is the first combination drug for HCV treatment. It is also the first HCV treatment that does not require the use of interferon and ribavirin.
Sovaldi, the previously approved sofosbuvir portion of the combination drug, is one of the most expensive drugs in the United States. Harvoni is expected to cost even more, according to the report.
More articles on gastroenterology:
CMS to cover stool DNA test Cologuard
UPMC GI scope infection research could alter national guidelines
How to boost efficiency without sacrificing quality in GI
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
